Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial (COMET): randomized controlled trial☆

[1]  P. Lundborg,et al.  Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: A comparison with conventional tablets , 2004, European Journal of Clinical Pharmacology.

[2]  Nick Freemantle,et al.  Composite outcomes in randomized trials: greater precision but with greater uncertainty? , 2003, JAMA.

[3]  B. Fagerberg,et al.  Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). , 2002, Journal of the American College of Cardiology.

[4]  P. Poole‐Wilson,et al.  Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET , 2002, European journal of heart failure.

[5]  K. Swedberg,et al.  Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.

[6]  Duolao Wang,et al.  Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure , 2001, European journal of heart failure.

[7]  J. Berlin,et al.  Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. , 2001, American heart journal.

[8]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[9]  A. Mallet,et al.  Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial , 2001, Circulation.

[10]  A. Zeiher,et al.  Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. , 2000, Journal of the American College of Cardiology.

[11]  M. Metra,et al.  Differential Effects of β-Blockers in Patients With Heart Failure , 2000 .

[12]  R Dietz,et al.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. , 2000, JAMA.

[13]  K. Woo,et al.  Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. , 1999, Journal of the American College of Cardiology.

[14]  L. Mestroni,et al.  Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol , 1999 .

[15]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[16]  D E Grobbee,et al.  The epidemiology of heart failure. , 1997, European heart journal.

[17]  W. Abraham,et al.  Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. , 1996, Circulation.

[18]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[19]  S. Jacob,et al.  Differential effect of chronic treatment with two beta‐blocking agents on insulin sensitivity: the carvedilol‐metoprolol study , 1996, Journal of hypertension.

[20]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[21]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[22]  Hung‐Yuan Cheng,et al.  Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. , 1992, The Journal of pharmacology and experimental therapeutics.

[23]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.

[24]  E. Varnauskas,et al.  Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. , 1975, British heart journal.